Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Size to Reach USD 64.09 Billion by 2033 | Growing at a 35.3% CAGR Driven by Precision Medicine, RNAi Therapies, and Early Disease Diagnosis

The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market was valued at USD 5.85 billion in 2025 and is projected to reach USD 64.09 billion by 2033, growing at a CAGR of 35.3% during the forecast period from 2026 to 2033. The market is witnessing exceptional growth driven by increasing awareness of rare cardiac diseases, improved diagnostic capabilities, and the rapid development of disease-modifying therapies. ATTR-CM, once considered an underdiagnosed condition, is now receiving significant clinical attention due to advancements in genetic testing, non-invasive imaging, and biomarker-based diagnosis. Growing adoption of precision medicine and rising investments in rare disease research are further accelerating market expansion.

The market is further fueled by the commercialization of next-generation transthyretin stabilizers, gene-silencing therapies, RNA-based treatments, and CRISPR-based gene-editing technologies that aim to slow or halt disease progression. Pharmaceutical companies are actively expanding clinical trials, securing regulatory approvals, and forming strategic partnerships to strengthen their ATTR-CM portfolios. In addition, increasing screening among elderly populations and patients with unexplained heart failure, along with favorable orphan drug incentives and improving reimbursement frameworks, is creating substantial growth opportunities. As innovation in cardiovascular precision medicine continues to advance, the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market is expected to offer exceptional long-term opportunities for biopharmaceutical companies, healthcare providers, and investors worldwide.

Get a Free Sample PDF of This Report (Get Higher Priority for Corporate Email ID):https://www.datamintelligence.com/download-sample/transthyretin-amyloid-cardiomyopathy-market?sai-v

Key Developments
July 2026: The United States strengthened ATTR-CM treatment innovation as BridgeBio Pharma advanced the clinical development of next-generation transthyretin-targeted therapies, expanding options for patients with transthyretin amyloid cardiomyopathy.

June 2026: United States-based Pfizer Inc. expanded global access to Vyndaqel (tafamidis) through new market initiatives and continued clinical evidence supporting improved outcomes in patients with transthyretin amyloid cardiomyopathy.

May 2026: The United Kingdom accelerated research into transthyretin amyloidosis as AstraZeneca advanced precision medicine collaborations focused on earlier diagnosis and targeted treatment strategies for ATTR-CM.

April 2026: United States-based Alnylam Pharmaceuticals expanded the clinical development of RNA interference (RNAi)-based therapies targeting transthyretin (TTR), supporting next-generation treatment approaches for ATTR-CM.

March 2026: Switzerland strengthened rare disease innovation as Ionis Pharmaceuticals collaborated with global healthcare partners to advance antisense oligonucleotide therapies targeting transthyretin-mediated amyloidosis.

February 2026: Europe witnessed increasing collaborations between pharmaceutical companies, academic institutions, and cardiovascular research centers to improve early diagnosis, genetic screening, and disease management for transthyretin amyloid cardiomyopathy.

January 2026: North America experienced growing investments in precision medicine, advanced cardiac imaging, and biomarker research, supporting earlier detection and improved treatment outcomes for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

Key Players
Pfizer Inc. | Alnylam Pharmaceuticals, Inc. | BridgeBio Pharma, Inc. | AstraZeneca plc | Ionis Pharmaceuticals, Inc. | Bayer AG | Novo Nordisk A/S | Eli Lilly and Company | Bristol Myers Squibb | Johnson & Johnson | Others

Key Highlights
Pfizer Inc. - Holds a 46.8% share, driven by the commercial success of Vyndaqel® and Vyndamax® (tafamidis), strong clinical evidence, broad regulatory approvals, and its established global commercialization network for ATTR-CM treatment.

Alnylam Pharmaceuticals, Inc. - Holds a 18.4% share, supported by Amvuttra® (vutrisiran), advanced RNA interference (RNAi) technology, expanding clinical indications, and a robust rare disease portfolio.

BridgeBio Pharma, Inc. - Holds a 12.7% share, strengthened by Attruby® (acoramidis), next-generation transthyretin stabilization technology, positive Phase III clinical outcomes, and increasing physician adoption.

AstraZeneca plc - Holds a 5.4% share, driven by strategic investments in rare cardiovascular diseases, precision medicine initiatives, and collaborations in innovative therapeutics.

Ionis Pharmaceuticals, Inc. - Holds a 4.3% share, supported by its antisense oligonucleotide platform, pipeline therapies targeting transthyretin-mediated diseases, and strong R&D capabilities.

Bayer AG - Holds a 3.2% share, strengthened by its cardiovascular therapeutic expertise, global commercial infrastructure, and continued investment in rare disease research.

Novo Nordisk A/S - Holds a 2.4% share, fueled by expanding investments in cardiovascular disease therapeutics and innovative biologics development.

Eli Lilly and Company - Holds a 2.1% share, supported by its cardiovascular research capabilities, precision medicine initiatives, and growing pipeline in specialty therapeutics.

Bristol Myers Squibb - Holds a 1.7% share, driven by its expertise in cardiovascular drug development, strategic partnerships, and expanding rare disease research programs.

Johnson & Johnson - Holds a 1.3% share, strengthened by its global pharmaceutical business, advanced biologics research, and investments in innovative cardiovascular therapies.

Others - Hold a combined 1.7% share, comprising biotechnology firms, academic spin-offs, and emerging pharmaceutical companies developing novel transthyretin stabilizers, gene-silencing therapies, and disease-modifying treatments for ATTR-CM.

Buy Now - Get Instant Access to the Full Market Report: https://www.datamintelligence.com/buy-now-page?report=transthyretin-amyloid-cardiomyopathy-market?sai-v

Market Drivers
Increasing prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM), rising aging population, and growing incidence of heart failure are significantly driving growth of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market worldwide.

Growing awareness among healthcare professionals regarding early diagnosis and disease management is accelerating adoption of advanced diagnostic tools and targeted ATTR-CM therapies.

Advancements in transthyretin stabilizers, gene-silencing therapies, RNA interference (RNAi) technologies, and next-generation disease-modifying treatments are strengthening market expansion and improving patient outcomes.

Increasing availability of advanced diagnostic technologies, including echocardiography, cardiac magnetic resonance imaging (MRI), nuclear scintigraphy, and genetic testing, is improving early detection and treatment initiation.

Rising investments by pharmaceutical companies, biotechnology firms, and research organizations in novel drug development, clinical trials, and precision medicine are supporting market growth.

Expansion of regulatory approvals for innovative ATTR-CM therapies and increasing reimbursement support are improving patient access to advanced treatment options.

Growing emphasis on personalized medicine, multidisciplinary cardiac care, and early intervention strategies is increasing demand for effective ATTR-CM treatment solutions.

Continuous innovation in biomarker research, genetic diagnostics, artificial intelligence-enabled disease screening, and digital patient monitoring is further propelling the global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market.

Industry Developments
Rapid advancement in transthyretin stabilizers, RNA interference (RNAi) therapies, antisense oligonucleotide therapies, and CRISPR-based gene-editing research improving disease management and long-term clinical outcomes.

Increasing adoption of precision diagnostics, genetic screening, cardiac imaging technologies, and biomarker-based disease monitoring supporting earlier diagnosis and personalized treatment.

Growing investments in late-stage clinical trials, orphan drug development, and next-generation therapeutics accelerating innovation across the ATTR-CM treatment ecosystem.

Expansion of collaborations among pharmaceutical companies, biotechnology firms, academic institutions, and healthcare providers driving development of novel disease-modifying therapies.

Rising focus on combination therapies, long-term disease monitoring, and real-world evidence generation enhancing treatment optimization and patient management.

Strategic regulatory approvals, product launches, acquisitions, licensing agreements, and pipeline expansion initiatives by leading biopharmaceutical companies supporting global market growth.

Continuous improvements in diagnostic accuracy, patient identification, genetic counseling, and multidisciplinary care pathways enhancing clinical outcomes and expanding treatment accessibility.

Regional Insights
North America 46.2% share: Leads the market due to advanced healthcare infrastructure, high awareness of rare cardiovascular diseases, favorable reimbursement policies, strong presence of leading biopharmaceutical companies, and widespread availability of innovative ATTR-CM therapies.

Europe 29.1% share: Strong market presence driven by increasing adoption of precision medicine, expanding access to advanced diagnostics, supportive regulatory frameworks, and growing investments in rare disease research.

Asia Pacific 18.7% share: Fastest-growing region supported by expanding healthcare infrastructure, increasing awareness of ATTR-CM, improving diagnostic capabilities, growing clinical research activities, and rising adoption of advanced cardiovascular therapies across Japan, China, South Korea, and India.

Latin America 3.5% share: Growth supported by improving access to specialized cardiovascular care, increasing awareness of rare diseases, and expanding availability of advanced diagnostic technologies, particularly in Brazil and Mexico.

Middle East & Africa 2.5% share: Emerging growth driven by healthcare modernization initiatives, improving rare disease diagnosis, increasing investments in specialty healthcare services, and gradual adoption of innovative ATTR-CM therapies.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/transthyretin-amyloid-cardiomyopathy-market?sai-v
Key Segments
➥ By Type

Familial (Hereditary) ATTR-CM: Represents a significant segment, driven by increasing genetic screening, early diagnosis, and growing availability of targeted therapies.

Wild-type ATTR-CM: Represents the dominant segment, supported by the rising prevalence among the aging population and improved awareness of the disease.

➥ By Drug Type

Transthyretin Stabilizers: Represents the dominant segment, driven by strong clinical adoption and proven efficacy in slowing disease progression and improving patient outcomes.

RNAi Therapy: Represents a rapidly growing segment, supported by advancements in gene-silencing technologies and increasing approvals of innovative RNA-based treatments.

Others: Represents a growing segment, fueled by ongoing development of gene-editing therapies, TTR silencers, amyloid degraders, and other novel treatment approaches.

➥ By Distribution Channel

Hospital Pharmacies: Represents the dominant segment, driven by the administration of specialty therapies, comprehensive patient management, and treatment initiation in hospital settings.

Retail Pharmacies: Represents a significant segment, supported by increasing availability of oral therapies and improved access for long-term disease management.

Online Pharmacies: Represents a rapidly growing segment, fueled by the expansion of digital healthcare platforms, home delivery services, and increasing patient preference for convenient medication access.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: fabian@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.